Acute Effects of Zynamite® S in Cognitive Function and Mood

NCT ID: NCT07126717

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-12

Study Completion Date

2025-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study sought to confirm the cognitive and mood benefits of a standardized soluble mango leaf extract, named as Zynamite® S. A placebo or a single dose of the botanical extract (100 mg) was administered and its acute effects on mental function and mood were evaluated before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study is a double-blind, randomized, placebo-controlled crossover clinical trial that aimed to evaluate the effects of a standardized soluble mango leaf extract (Zynamite® S) on cognitive performance and mood. The study included 88 healthy university students aged 18-25 years. Participants received a single 100 mg dose of Zynamite® S or a placebo. Cognitive performance was evaluated by using the Trail Making Test (TMT) to assess executive functions, the Digit Symbol Substitution Test (DSST) for processing speed, and the Stroop Color and Word Test and the Stroop Interference Test to evaluate selective attention and cognitive flexibility. Additionally, mood was assessed using the Spanish short version of the Profile of Mood States (POMS). All the assessments were conducted before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Performance Mood

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Capsule containing food-grade maltodextrin

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Food-grade maltodextrin

Zynamite® S 100mg

Capsule containing 100 mg of soluble mango leaf extract (Zynamite® S) standardized to 60% of mangiferin

Group Type EXPERIMENTAL

Zynamite® S

Intervention Type DIETARY_SUPPLEMENT

Water-soluble mango leaf extract standardized to 60% of mangiferin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Food-grade maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Zynamite® S

Water-soluble mango leaf extract standardized to 60% of mangiferin

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being registered as an undergraduate or postgraduate university student
* Being between 18 and 25 years old
* Being healthy and free of any relevant medical condition or illness

Exclusion Criteria

* Suffering from chronic diseases such as asthma, type 1 diabetes, thyroid diseases (such as hypothyroidism or hyperthyroidism), autoimmune disorders (such as Crohn's disease), and psychiatric conditions such as anxiety disorders, major depression, eating disorders (anorexia, bulimia), attention deficit hyperactivity disorder (ADHD), among others
* Being pregnant or lactating
* Having any known intolerance, hypersensitivity, or allergies to any of the ingredients of the investigational products
* Having intestinal malabsorption problems, as well as learning difficulties, dyslexia, eye problems, or color blindness
* Intaking of psychoactive substances or medications that could influence the study results, such as consuming \>500 mg of caffeine per day (\>6 cups of 150 ml filtered coffee) and/or alcohol
* Having comprehension or communication difficulties that prevent full understanding of the informed consent or effective participation in the study, such as autism spectrum disorders, aphasia, or intellectual disability
Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Atlántico Medio

UNKNOWN

Sponsor Role collaborator

Nektium Pharma SL

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Atlántico Medio

Tafira Baja, Las Palmas, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Castellote-Caballero Y, Beltran-Arranz A, Aibar-Almazan A, Carcelen-Fraile MDC, Rivas-Campo Y, Lopez-Rios L, Vega-Morales T, Gonzalez-Martin AM. Acute Supplementation of Soluble Mango Leaf Extract (Zynamite(R) S) Improves Mental Performance and Mood: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Pharmaceuticals (Basel). 2025 Apr 14;18(4):571. doi: 10.3390/ph18040571.

Reference Type BACKGROUND
PMID: 40284006 (View on PubMed)

Fuentes-Rios D, Sanchez-Rodriguez A, Lopez-Rios L, Garcia-Gonzalez E, Martinez-Canton M, Galvan-Alvarez V, Gallego-Selles A, Martin-Rincon M, Calbet JAL, Vega-Morales T. Human Pharmacokinetic Profiling and Comparative Analysis of Mangiferin and Its Monosodium Derivative from Mangifera indica Extracts Using UHPLC-MS/MS with 1H NMR and MALDI-TOF Confirmation. Molecules. 2025 Jan 21;30(3):461. doi: 10.3390/molecules30030461.

Reference Type BACKGROUND
PMID: 39942566 (View on PubMed)

Sharif S, Guirguis A, Fergus S, Schifano F. The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. Brain Sci. 2021 Mar 10;11(3):355. doi: 10.3390/brainsci11030355.

Reference Type BACKGROUND
PMID: 33802176 (View on PubMed)

Malik M, Tlustos P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients. 2022 Aug 17;14(16):3367. doi: 10.3390/nu14163367.

Reference Type BACKGROUND
PMID: 36014874 (View on PubMed)

Jangra A, Lukhi MM, Sulakhiya K, Baruah CC, Lahkar M. Protective effect of mangiferin against lipopolysaccharide-induced depressive and anxiety-like behaviour in mice. Eur J Pharmacol. 2014 Oct 5;740:337-45. doi: 10.1016/j.ejphar.2014.07.031. Epub 2014 Jul 23.

Reference Type BACKGROUND
PMID: 25064341 (View on PubMed)

Cao C, Su M, Zhou F. Mangiferin inhibits hippocampal NLRP3 inflammasome and exerts antidepressant effects in a chronic mild stress mice model. Behav Pharmacol. 2017 Aug;28(5):356-364. doi: 10.1097/FBP.0000000000000305.

Reference Type BACKGROUND
PMID: 28410265 (View on PubMed)

Lum PT, Sekar M, Gan SH, Pandy V, Bonam SR. Protective effect of mangiferin on memory impairment: A systematic review. Saudi J Biol Sci. 2021 Jan;28(1):917-927. doi: 10.1016/j.sjbs.2020.11.037. Epub 2020 Nov 13.

Reference Type BACKGROUND
PMID: 33424383 (View on PubMed)

Lei LY, Wang RC, Pan YL, Yue ZG, Zhou R, Xie P, Tang ZS. Mangiferin inhibited neuroinflammation through regulating microglial polarization and suppressing NF-kappaB, NLRP3 pathway. Chin J Nat Med. 2021 Feb;19(2):112-119. doi: 10.1016/S1875-5364(21)60012-2.

Reference Type BACKGROUND
PMID: 33641782 (View on PubMed)

Li HW, Lan TJ, Yun CX, Yang KD, Du ZC, Luo XF, Hao EW, Deng JG. Mangiferin exerts neuroprotective activity against lead-induced toxicity and oxidative stress via Nrf2 pathway. Chin Herb Med. 2019 Dec 14;12(1):36-46. doi: 10.1016/j.chmed.2019.12.002. eCollection 2020 Jan.

Reference Type BACKGROUND
PMID: 36117559 (View on PubMed)

Alberdi E, Sanchez-Gomez MV, Ruiz A, Cavaliere F, Ortiz-Sanz C, Quintela-Lopez T, Capetillo-Zarate E, Sole-Domenech S, Matute C. Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers. Oxid Med Cell Longev. 2018 Jun 14;2018:2856063. doi: 10.1155/2018/2856063. eCollection 2018.

Reference Type BACKGROUND
PMID: 30013719 (View on PubMed)

Lopez-Rios L, Wiebe JC, Vega-Morales T, Gericke N. Central nervous system activities of extract Mangifera indica L. J Ethnopharmacol. 2020 Oct 5;260:112996. doi: 10.1016/j.jep.2020.112996. Epub 2020 May 27.

Reference Type BACKGROUND
PMID: 32473365 (View on PubMed)

Wightman EL, Jackson PA, Forster J, Khan J, Wiebe JC, Gericke N, Kennedy DO. Acute Effects of a Polyphenol-Rich Leaf Extract of Mangifera indica L. (Zynamite) on Cognitive Function in Healthy Adults: A Double-Blind, Placebo-Controlled Crossover Study. Nutrients. 2020 Jul 23;12(8):2194. doi: 10.3390/nu12082194.

Reference Type BACKGROUND
PMID: 32717999 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZYNS_HCT_2025.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pomegranate Extract and Memory
NCT01950221 COMPLETED PHASE2
Nutraceutical Effects on Long-Term Memory
NCT01963767 COMPLETED PHASE2